A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors

What is the purpose of this trial?

The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1948 and determine the recommended Phase 2 dose (RP2D) of ASP1948. This study will also evaluate the antitumor effect of ASP1948.



Astellas Pharma US, Inc.

Start Date: 10/31/2018

End Date: 03/28/2021

Last Updated: 11/05/2018

Study HIC#: 2000023045

Get Involved

For more information about this study, contact:
Karen Forman
+1 203-671-0783
karen.forman@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image